You are viewing the site in preview mode
Skip to main content
|
Characteristics.
|
Type 1 CNV group (n = 77)
|
Type 2 CNV group (n = 53)
|
p-value
|
|---|
|
Age, years (mean ± SD)
|
74.2 ± 7.2
|
76.6 ± 7.3
|
0.067
|
|
Sex, male/female (%)
|
51/26 (66/34)
|
29/24 (55/45)
|
0.072
|
|
Lens status, phakic/pseudophakic (%)
|
57/20 (74/26)
|
33/20 (62/38)
|
0.153
|
|
Best-corrected visual acuity, logMAR (mean ± SD)
|
0.54 ± 0.30
|
0.75 ± 0.36
|
0.001
|
|
Central subfield retinal thickness, μm (mean ± SD)
|
398.06 ± 123.07
|
436.74 ± 131.05
|
0.089
|
|
Subfoveal choroidal thickness, μm (mean ± SD)
|
293.64 ± 79.97
|
229.32 ± 76.76
|
< 0.001
|
|
Anti-VEGF, n (%)
| | |
0.324
|
|
Bevacizumab
|
10 (13)
|
5 (9)
| |
|
Ranibizumab
|
12 (15)
|
12 (23)
| |
|
Aflibercept
|
39 (51)
|
20 (38)
| |
|
Mixed
|
16 (21)
|
16 (30)
| |
|
No. of intravitreal anti-VEGF injections (mean ± SD)
|
|
1 year
|
7.0 ± 1.6
|
6.8 ± 1.4
|
0.436
|
|
2 year
|
5.1 ± 1.9
|
5.1 ± 1.4
|
0.940
|
|
Total
|
12.0 ± 3.0
|
11.8 ± 2.4
|
0.631
|
|
Fluid on OCT at baseline, n (%)
|
|
SRF
|
77 (100)
|
49 (92)
|
0.014
|
|
IRF
|
2 (3)
|
39 (74)
|
< 0.001
|
- CNV choroidal neovascularization, SD standard deviation, logMAR logarithm of the minimal angle of resolution, VEGF vascular endothelial growth factor, OCT optical coherence tomography
